The DOI matches its Crossref record; 198 of the 206 references it cites were found in a registry or an index; 31 of the 258 sources its claims cite were checked for support.
Steroid Metabolome Analysis in Disorders of Adrenal Steroid Biosynthesis and Metabolism
Open accessAbstract
Steroid biosynthesis and metabolism are reflected by the serum steroid metabolome and, in even more detail, by the 24-hour urine steroid metabolome, which can provide unique insights into alterations of steroid flow and output indicative of underlying conditions. Mass spectrometry–based steroid metabolome profiling has allowed for the identification of unique multisteroid signatures associated with disorders of steroid biosynthesis and metabolism that can be used for personalized approaches to diagnosis, differential diagnosis, and prognostic prediction. Additionally, steroid metabolome analysis has been used successfully as a discovery tool, for the identification of novel steroidogenic disorders and pathways as well as revealing insights into the pathophysiology of adrenal disease. Increased availability and technological advances in mass spectrometry–based methodologies have refocused attention on steroid metabolome profiling and facilitated the development of high-throughput steroid profiling methods soon to reach clinical practice. Furthermore, steroid metabolomics, the combination of mass spectrometry–based steroid analysis with machine learning–based approaches, has facilitated the development of powerful customized diagnostic approaches. In this review, we provide a comprehensive up-to-date overview of the utility of steroid metabolome analysis for the diagnosis and management of inborn disorders of steroidogenesis and autonomous adrenal steroid excess in the context of adrenal tumors.
Overview
CoChat Summary
TL;DR
This review describes how serum and 24-hour urine steroid metabolome profiling, especially mass spectrometry–based multisteroid analysis, reveals distinct signatures of inborn steroid biosynthesis/metabolism disorders and autonomous adrenal steroid excess. It highlights steroid metabolomics—mass spectrometry plus machine learning—as a diagnostic, discovery, and prognostic tool, with an ACC malignant steroid fingerprint awaiting prospective validation.
Key findings
- The 24-hour urine steroid metabolome measures net steroid output and can reveal underlying enzymatic deficiencies and autonomous adrenal steroid excess; urinary excretion accounts for ∼80% of steroid excretion.
- Inborn errors show characteristic multisteroid signatures: >90% of congenital adrenal hyperplasia cases are caused by CYP21A2 deficiency, and diagnostic ratios can distinguish disorders, e.g., 5PT/PTONE is typically low (<1.5) in CYP21A2 deficiency but high (>35) in HSD3B2 deficiency.
- In adrenal tumors, routine serum biochemistry detects steroid excess in 60% to 70% of adrenocortical carcinoma (ACC) patients, whereas urine GC-MS profiling demonstrates steroid excess in >90%; a machine learning–derived “malignant steroid fingerprint” can differentiate ACC from adrenocortical adenoma with high sensitivity and specificity.
- Primary aldosteronism affects at least 5% of the hypertensive population, and many patients also cosecrete glucocorticoid and 11-oxygenated androgen metabolites (“Connshing syndrome”); adrenal masses are estimated in 5% of the general population, with only 5% of those being cortisol-producing adenomas manifesting as adrenal Cushing syndrome.
Methods
- Narrative review of published literature; no primary data or new patient cohort are presented.
- Synthesizes mass spectrometry–based steroid profiling approaches, including GC-MS for comprehensive urine steroid metabolite profiling and UHPLC-MS/MS for serum/plasma steroids and, more recently, urine steroid metabolites.
- Focuses on steroid metabolomics—combining mass spectrometry–based steroid analysis with machine learning–based data analysis—for diagnosis, differential diagnosis, and prognostic prediction in inborn steroidogenic disorders and autonomous adrenal steroid excess.
Limitations
- The paper states no formal limitations.
- Evident from the text: as a review, it provides no new primary data, and some cited evidence is retrospective or preliminary; the large-scale prospective validation study of the ACC urine steroid metabolomics test has been completed but results are awaited.
- Evident from the text: there is a paucity of published urine steroid profiling data in HSD17B3 deficiency, and no distinct steroid metabolome signature has been identified for other primary aldosteronism–causing mutations, mostly due to rarity of cases.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
23 Valid · 11 Not valid · 120 Not checked · 59 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“The combination of mass spectrometry–based steroid profiling with machine learning–based data analysis has created a powerful discovery tool, steroid metabolomics, highly suited as a diagnostic biomarker approach (1–4).”
§ Steroid Metabolome Analysis in Disorders of Adrenal Steroid Biosynthesis and Metabolism > Abstract
What the sources say
- Supportedcites [1] Arlt, 2011, Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors, J Clin Endocrinol Metab source
The Objective describes mass spectrometry-based steroid profiling followed by machine learning analysis as a steroid metabolomic approach. The Discussion calls the combination a highly promising biomarker approach for differentiating adrenal tumors, while noting that prospective validation is needed before routine clinical use. (LLM, conf=0.91)
- Not checked yetcites [2] Biehl M , SchneiderP, SmithDJ, StiekemaH, TaylorAE, HughesBA, ShackletonCHL, StewartPM, ArltW. Matrix relevance LVQ in steroid metabolomics based classification of adrenal tumors. Available at: www.i6doc.com/en/livre/?GCOI=28001100967420. Accessed 30 April 2019.
- Not checked yetcites [3] Bunte, 2018, Learning pharmacokinetic models for in vivo glucocorticoid activation, J Theor Biol source
- Not checked yetcites [4] Thomson, 2019, Simultaneous parameter estimation and variable selection via the logit-normal continuous analogue of the spike-and-slab prior, J R Soc Interface source
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“P450 oxidoreductase (POR) is the crucial electron donor for microsomal cytochrome P450 (CYP) enzymes, including the steroidogenic enzymes CYP21A2, CYP17A1, and, to a lesser degree, CYP19A1 (11, 12).”
§ Steroid Metabolome Analysis in Disorders of Adrenal Steroid Biosynthesis and Metabolism > Steroid Metabolome Signatures of Inborn Errors of Steroid Biosynthesis and Metabolism > The steroid metabolome in congenital adrenal hyperplasia
What the sources say
- Supportedcites [11] Baranowski, 2018, Monogenic disorders of adrenal steroidogenesis, Horm Res Paediatr source
The “POR Deficiency” passage in the section “Monogenic Disorders Affecting Co-Factor Enzymes of Steroidogenesis” states the claim directly, including the lesser role of CYP19A1. The supplied passage does not specify a page. (LLM, conf=0.95)
- Partly supportedcites [12] Miller, 2011, The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders, Endocr Rev sourceExperimental — accuracy not yet measured
The “P450 oxidoreductase” section identifies POR as the sole electron-transfer protein for all microsomal P450s, including P450c21, P450c17, and P450aro. It does not establish that POR donates electrons to P450aro (CYP19A1) to a lesser degree; the “P450 oxidoreductase deficiency” section instead describes mutation-specific effects on P450aro activity. Page numbers are unavailable in our copy. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In contrast to 17,20-lyase deficiency in the context of CYP17A1 deficiency (see “CAH due to CYP21A2 deficiency” above), which always comes with a degree of impairment of CYP17A1 17α-hydroxylase activity, CYB5A deficiency represents “true” isolated 17,20-lyase deficiency (15, 70);”
§ Steroid Metabolome Analysis in Disorders of Adrenal Steroid Biosynthesis and Metabolism > Steroid Metabolome Signatures of Inborn Errors of Steroid Biosynthesis and Metabolism > Inborn disorders of androgen biosynthesis and metabolism
What the sources say
- Supportedcites [15] Idkowiak, 2012, A missense mutation in the human cytochrome b5 gene causes 46,XY disorder of sex development due to true isolated 17,20 lyase deficiency, J Clin Endocrinol Metab source
The Discussion (page not specified) reports preserved 17α-hydroxylase activity with 17,20-lyase deficiency in the CYB5A-affected family. It contrasts this with previously reported CYP17A1-associated cases, in which 17α-hydroxylase activity was also impaired. (LLM, conf=0.91)
- Not checked yetcites [70] Kok, 2010, Isolated 17,20-lyase deficiency due to the cytochrome b5 mutation W27X, J Clin Endocrinol Metab source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“However, several previous studies did not find clinically significant androgen deficiency in affected patients (74–78).”
§ Steroid Metabolome Analysis in Disorders of Adrenal Steroid Biosynthesis and Metabolism > Steroid Metabolome Signatures of Inborn Errors of Steroid Biosynthesis and Metabolism > Inborn disorders of sulfation and desulfation
What the sources say
- Not checked yetcites [74] Sánchez-Guijo, 2016, Role of steroid sulfatase in steroid homeostasis and characterization of the sulfated steroid pathway: evidence from steroid sulfatase deficiency, Mol Cell Endocrinol source
- Not checked yetcites [75] Delfino, 1998, X-linked ichthyosis: relation between cholesterol sulphate, dehydroepiandrosterone sulphate and patient’s age, Br J Dermatol source
- Not checked yetcites [76] Lykkesfeldt, 1985, Abnormal androgen and oestrogen metabolism in men with steroid sulphatase deficiency and recessive X-linked ichthyosis, Clin Endocrinol (Oxf) source
- Partly supportedcites [77] Idkowiak, 2016, Steroid sulfatase deficiency and androgen activation before and after puberty, J Clin Endocrinol Metab sourceExperimental — accuracy not yet measured
The paper states in its introductory discussion that severe androgen deficiency had not been reported in STS deficiency. However, its Discussion says earlier studies provided little detailed clinical information, and one prior cohort found mild biochemical androgen deficiency. It therefore supports the absence of reported severe deficiency, but not the stronger implication that several studies assessed and found no clinically significant deficiency. (LLM, conf=0.81)
- Not checked yetcites [78] Ruokonen, 1986, Regulation of serum testosterone in men with steroid sulfatase deficiency: response to human chorionic gonadotropin, J Steroid Biochem source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“CRD is caused by HSD11B1 deficiency (90) whereas ACRD results form a deficiency in the activity of H6PDH, which is essential for maintaining the reductive activity of HSD11B1 in vivo by the reduced form of NAD phosphate provision to the enzyme (91, 92).”
§ Steroid Metabolome Analysis in Disorders of Adrenal Steroid Biosynthesis and Metabolism > Steroid Metabolome Signatures of Inborn Errors of Steroid Biosynthesis and Metabolism > Inborn disorders of cortisol activation and inactivation
What the sources say
- Not checked yetcites [91] Draper, 2003, Mutations in the genes encoding 11β-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency, Nat Genet source
- Supportedcites [92] Lavery, 2008, Steroid biomarkers and genetic studies reveal inactivating mutations in hexose-6-phosphate dehydrogenase in patients with cortisone reductase deficiency, J Clin Endocrinol Metab source
The paper’s conclusions report that inactivating H6PD mutations cause cortisone reductase deficiency and prevent 11β-HSD1 from functioning as an oxoreductase. Its introductory passage explains that H6PDH supplies the NADPH required for 11β-HSD1 reductase activity in vivo, matching the mechanism attributed to this source. (LLM, conf=0.91)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
88 more claims · 7 with their cited sources checked
Create a free account to see all 213 claims and to verify the 227 references still open.
- It may state two separate claims as one. 109
- Probably not a substantial claim. 22
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In patients with NC CAH, 11-oxo-androgens are elevated about 2-fold compared to women with clinical features of androgen excess, although 11-oxo-androgens alone cannot be used to establish the diagnosis of NC CAH (131).”
From Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management (2022) · cites this paper as [131]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Studies of the steroid profile of patients with congenital adrenal hyperplasia due to deficiencies of 17α-, 11β- or 21-hydroxylase (and POR), corroborate this physiological data, reinforcing the concept of a “MC (or non-17-hydroxylated) pathway of ZF ” ( 3 , 7 - 9 , 18 ).”
From Classic and current concepts in adrenal steroidogenesis: a reappraisal (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, in 17OHD serum levels of B reach values 100 times higher than normal, in the range of 15 to 50 mcg/dL (normal: 0.1 to 0.6 mcg/dL).”
From Classic and current concepts in adrenal steroidogenesis: a reappraisal (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although its GC activity is 10 times lower than cortisol, its abundant concentration provides enough GC activity to prevent “addisonian” manifestations in the affected patient ( 3 , 7 , 8 , 20 ).”
From Classic and current concepts in adrenal steroidogenesis: a reappraisal (2022) · cites this paper as [3]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“(i) DOC secretion is amplified by exogenous ACTH stimulation and easily blocked by dexamethasone administration”
From Classic and current concepts in adrenal steroidogenesis: a reappraisal (2022) · cites this paper as [3]
Experimental — accuracy not yet measured
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Steroid Metabolome Analysis in Disorders of Adrenal Steroid Biosynthesis and Metabolism > Steroid Metabolome Signatures of Inborn Errors of Steroid Biosynthesis and Metabolism > Inborn disorders of androgen biosynthesis and metabolism
“In contrast to 17,20-lyase deficiency in the context of CYP17A1 deficiency (see “CAH due to CYP21A2 deficiency” above)”
§ Steroid Metabolome Analysis in Disorders of Adrenal Steroid Biosynthesis and Metabolism > Steroid Metabolome Signatures of Inborn Errors of Steroid Biosynthesis and Metabolism > The steroid metabolome in congenital adrenal hyperplasia
“#### CAH due to CYP17A1 deficiency”
Citations
Cites
Funder, J. W., Carey, R. M., Mantero, F., Murad, M. H., Reincke, M., Shibata, H., Stowasser, M., & Young, W. F. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-4061 · Cited by 2,925
The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0125 · Cited by 2,718
The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders
Miller, W. L., & Auchus, R. J. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0013 · Cited by 2,458
Arriza, J. L., Weinberger, C., Cerelli, G., Glaser, T. M., Handelin, B. L., Housman, D. E., & Evans, R. M. (1987) · Science · doi:10.1126/science.3037703 · Cited by 1,946
Lacroix, A., Feelders, R. A., Stratakis, C. A., & Nieman, L. K. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61375-1 · Cited by 1,777
Fassnacht, M., Arlt, W., Bancos, I., Dralle, H., Newell-Price, J., Sahdev, A., Tabarin, A., Terzolo, M., Tsagarakis, S., & Dekkers, O. M. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0467 · Cited by 1,566
Self-citationEvidence for an increased rate of cardiovascular events in patients with primary aldosteronism
Milliez, P., Girerd, X., Plouin, P.-F., Blacher, J., Safar, M. E., & Mourad, J.-J. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.01.015 · Cited by 1,547
Lifton, R. P., Dluhy, R. G., Powers, M., Rich, G. M., Cook, S., Ulick, S., & Lalouel, J.-M. (1992) · Nature · doi:10.1038/355262a0 · Cited by 1,158
K + Channel Mutations in Adrenal Aldosterone-Producing Adenomas and Hereditary Hypertension
Choi, M., Scholl, U. I., Yue, P., Björklund, P., Zhao, B., Nelson-Williams, C., Ji, W., Cho, Y., Patel, A., Men, C. J., et al. (2011) · Science · doi:10.1126/science.1198785 · Cited by 1,004
Else, T., Kim, A. C., Sabolch, A., Raymond, V. M., Kandathil, A., Caoili, E. M., Jolly, S., Miller, B. S., Giordano, T. J., & Hammer, G. D. (2014) · Endocrine Reviews · doi:10.1210/er.2013-1029 · Cited by 892
Cited by
Small molecule metabolites: discovery of biomarkers and therapeutic targets
Qiu, S., Cai, Y., Yao, H., Lin, C., Xie, Y., Tang, S., & Zhang, A. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01399-3 · Cited by 884
Congenital Adrenal Hyperplasia—Current Insights in Pathophysiology, Diagnostics, and Management
Claahsen - van der Grinten, H. L., Speiser, P. W., Ahmed, S. F., Arlt, W., Auchus, R. J., Falhammar, H., Flück, C. E., Guasti, L., Huebner, A., Kortmann, B. B. M., et al. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab016 · Cited by 556
Self-citationSherlock, M., Scarsbrook, A., Abbas, A., Fraser, S., Limumpornpetch, P., Dineen, R., & Stewart, P. M. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa008 · Cited by 347
“This has been extensively reviewed by Storbeck et al. (344).”
Congenital adrenal hyperplasia
Auer, M. K., Nordenström, A., Lajic, S., & Reisch, N. (2023) · The Lancet · doi:10.1016/s0140-6736(22)01330-7 · Cited by 215
The Biosynthesis of Enzymatically Oxidized Lipids
Hajeyah, A. A., Griffiths, W. J., Wang, Y., Finch, A. J., & O’Donnell, V. B. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.591819 · Cited by 180
Metadata
- Authors
- Storbeck, K.-H., Schiffer, L., Baranowski, E. S., Chortis, V., Prete, A., Barnard, L., Gilligan, L. C., Taylor, A. E., Idkowiak, J., Arlt, W., & Shackleton, C. H. L.
- Affiliations
- Stellenbosch University (ZA)
- University of Birmingham (GB)
- Birmingham Women’s and Children’s NHS Foundation Trust (GB)
- University Hospitals Birmingham NHS Foundation Trust (GB)
- University of California, San Francisco (US)
- Corresponding author
- Arlt, Wiebke
- ORCID
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2019-07-11
- Volume
- 40
- Issue
- 6
- Pages
- 1605-1625
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- PMC
- PMC6858476
- OpenAlex
- W2960176468
- Semantic Scholar
- 807dd6287c13d38cf71f318250f2bb11b80bb36b
- Cited by
- 141
- References
- 206
- Citations by year
- 2026: 16 · 2025: 22 · 2024: 21 · 2023: 25 · 2022: 26 · 2021: 13 · 2020: 14 · 2019: 3
- FWCI
- 11.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Endocrine Reviews (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion, cc-by)
- SUNScholar (Stellenbosch University) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion, cc-by)
- Funders
- Wellcome Trust (WT209492/Z/17/Z, WT101671AIA)
- Medical Research Council (G1001964, MR/R017913/1)
- Diabetes UK (18/0005782)
- Academy of Medical Sciences UK (NAF004\1002)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Keywords
- steroid metabolome, adrenal steroidogenesis, serum steroids, adrenal tumors, personalized diagnosis, differential diagnosis, outcome prediction, machine learning
- MeSH terms
- Adrenal Gland Diseases, Diagnosis, Differential, Humans, Steroid Metabolism, Inborn Errors, Metabolome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Steroid Metabolome Analysis in Disorders of Adrenal Steroid Biosynthesis and Metabolism. https://app.cochat.ai/papers/10.1210/er.2018-00262
- The paper
- Storbeck, K.-H., Schiffer, L., Baranowski, E. S., Chortis, V., Prete, A., Barnard, L., Gilligan, L. C., Taylor, A. E., Idkowiak, J., Arlt, W., & Shackleton, C. H. L. (2019). Steroid Metabolome Analysis in Disorders of Adrenal Steroid Biosynthesis and Metabolism. Endocrine Reviews. https://doi.org/10.1210/er.2018-00262
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.